Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Loncar Cancer Immunotherapy ETF (CNCR)

Loncar Cancer Immunotherapy ETF (CNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Exchange Traded Concepts
  • Assets Under Management 44,233,000
  • Shares Outstanding, K 1,400
  • 60-Month Beta 1.17
Trade CNCR with:
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.29 (0.93%)
  • Most Recent Dividend 0.288 on 12/30/20
  • Management Fee 0.79%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.94 +4.61%
on 09/20/21
31.70 -1.20%
on 09/03/21
+0.72 (+2.35%)
since 08/27/21
3-Month
27.28 +14.81%
on 08/20/21
32.99 -5.06%
on 07/02/21
-0.58 (-1.82%)
since 06/25/21
52-Week
26.17 +19.68%
on 10/30/20
35.82 -12.56%
on 02/08/21
+4.38 (+16.27%)
since 09/25/20

Most Recent Stories

More News
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

PFE : 43.57 (-0.84%)
CNCR : 31.32 (+1.05%)
TRIL : 17.73 (+1.14%)
BBC : 48.35 (+1.60%)
XBI : 131.85 (+1.14%)
SBIO : 47.60 (+2.28%)
IBBJ : 30.64 (+1.26%)
Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

PFE : 43.57 (-0.84%)
MRNA : 408.84 (-4.95%)
TBIO : 37.36 (-0.13%)
IBB : 167.51 (-1.75%)
CNCR : 31.32 (+1.05%)
EDIT : 57.84 (-1.48%)
XBI : 131.85 (+1.14%)
CRSP : 117.26 (+0.71%)
CHNA : 37.30 (-0.84%)
BNTX : 307.09 (-7.91%)
CVAC : 56.19 (-3.19%)
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

AZN : 58.72 (-2.70%)
MRNA : 408.84 (-4.95%)
NVAX : 231.04 (-6.90%)
IBB : 167.51 (-1.75%)
CNCR : 31.32 (+1.05%)
XBI : 131.85 (+1.14%)
PPH : 73.24 (-0.46%)
BBH : 208.45 (-2.87%)
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

PFE : 43.57 (-0.84%)
MRNA : 408.84 (-4.95%)
LLY : 226.40 (-2.28%)
IBB : 167.51 (-1.75%)
CNCR : 31.32 (+1.05%)
XBI : 131.85 (+1.14%)
BBH : 208.45 (-2.87%)
FBT : 170.67 (-1.29%)
SBIO : 47.60 (+2.28%)
PBE : 76.47 (-1.33%)
BTEC : 56.53 (+0.22%)
ARKG : 78.25 (-0.51%)
BNTX : 307.09 (-7.91%)
Biotech ETFs Soar on Gilead-Immunomedics Deal

The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

GILD : 70.41 (-1.10%)
IMMU : 87.86 (+0.05%)
CNCR : 31.32 (+1.05%)
XBI : 131.85 (+1.14%)
PTH : 168.72 (-1.39%)
BBC : 48.35 (+1.60%)
ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial

AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.

IBB : 167.51 (-1.75%)
CNCR : 31.32 (+1.05%)
XBI : 131.85 (+1.14%)
PPH : 73.24 (-0.46%)
BBH : 208.45 (-2.87%)
7 Top ETFs That Trumped Last Week's Market Rout

Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.

CNCR : 31.32 (+1.05%)
ITB : 69.67 (+0.85%)
PGM : 45.97 (+0.25%)
WIL : 96.06 (+0.39%)
GRU : 4.39 (+2.09%)
EPHE : 29.84 (-0.96%)
DWSH : 8.71 (-0.68%)
6 Sector ETFs Surviving the Market Rout

Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.

AZN : 58.72 (-2.70%)
CNCR : 31.32 (+1.05%)
TAN : 82.06 (+1.89%)
ITB : 69.67 (+0.85%)
RING : 24.55 (-0.57%)
MXI : 87.36 (+0.25%)
GERM : 42.60 (-1.71%)
5 ETFs Jump After Three-Day Rout: Will The Rally Last?

We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

MSFT : 294.17 (-1.73%)
AZN : 58.72 (-2.70%)
AAPL : 145.37 (-1.05%)
TSLA : 791.36 (+2.19%)
CNCR : 31.32 (+1.05%)
PTH : 168.72 (-1.39%)
PBW : 80.46 (+2.41%)
ARKQ : 82.06 (+0.48%)
FNGS : 31.57 (unch)
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

MRNA : 408.84 (-4.95%)
IBB : 167.51 (-1.75%)
CNCR : 31.32 (+1.05%)
XBI : 131.85 (+1.14%)
BBH : 208.45 (-2.87%)
BTEC : 56.53 (+0.22%)
IDNA : 52.89 (-1.14%)
GERM : 42.60 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Fund Summary

The Loncar Cancer Immunotherapy ETF seeks investment results that correspond generally to the price and yield per for mance, before fees and expenses, of the Loncar Cancer Immunotherapy Index.

See More

Key Turning Points

3rd Resistance Point 31.21
2nd Resistance Point 31.13
1st Resistance Point 31.06
Last Price 31.32
1st Support Level 30.92
2nd Support Level 30.84
3rd Support Level 30.77

See More

52-Week High 35.82
Fibonacci 61.8% 32.13
Last Price 31.32
Fibonacci 50% 30.99
Fibonacci 38.2% 29.86
52-Week Low 26.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar